Stoke Therapeutics has appointed Thomas McCauley as Chief Scientific Officer. McCauley joins Stoke with more than 25 years of experience leading high-performing R&D teams and translating early scientific discoveries into clinical programs that have delivered new medicines to people living with severe diseases.
He brings extensive expertise in developing novel technology platforms and modalities across multiple therapeutic areas, including six years at Shire where he played a key role in the late-stage development and global approvals of multiple genetic medicines for rare diseases. In this new role, he will be responsible for leading Stoke’s scientific strategy and leveraging the Company’s proprietary RNA medicines platform to expand and advance its pipeline.
McCauley most recently served as the President and CEO of Neptune Bio, where he drove the company’s strategic vision and advanced therapeutic applications for its scientific platform. He was previously Chief Scientific Officer at Omega Therapeutics, Macrolide Pharmaceuticals and Translate Bio, where he led the advancement of each company’s scientific platform and drug development capabilities. Earlier in his career, McCauley held leadership and scientific roles at Shire, Inotek Pharmaceuticals and Archemix Corp. In these roles, he cultivated expertise in areas such as rare diseases and mRNA technologies. He currently serves as a Scientific Advisor for multiple early-stage biotechnology companies in the RNA and genetic therapeutics space.